PMID- 18459941
OWN - NLM
STAT- MEDLINE
DCOM- 20090220
LR  - 20181201
IS  - 1470-8736 (Electronic)
IS  - 0143-5221 (Linking)
VI  - 116
IP  - 1
DP  - 2009 Jan
TI  - Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats 
      after acute myocardial infarction.
PG  - 45-52
LID - 10.1042/CS20080042 [doi]
AB  - LV (left ventricular) remodelling is the basic mechanism of HF (heart failure) 
      following MI (myocardial infarction). Although there is evidence that 
      pro-inflammatory cytokines [including TNF-alpha (tumour necrosis factor-alpha) 
      and IL-6 (interleukin-6)] are involved in the remodelling process, only little is 
      known about the role of anti-inflammatory cytokines, such as IL-10. As 
      accumulating evidence has revealed that statins possess anti-inflammatory 
      properties, the aim of the present study was to elucidate the effect of 
      atorvastatin on the modulation of the anti-inflammatory cytokine IL-10 and its 
      effect on LV function in rats with HF subsequent to MI. Rats with MI, induced by 
      permanent LAD (left anterior descending) branch coronary artery ligation, were 
      treated for 4 weeks with atorvastatin (10 mg x kg(-1) of body weight x day(-1) 
      via oral gavage) starting on the first day after induction of MI. Cardiac 
      function was assessed by echocardiography and cardiac catheterization 4 weeks 
      after MI induction. Membrane-bound and soluble fractions of TNF-alpha, IL-6 and 
      IL-10 protein, the TNF-alpha/IL-10 ratio, serum levels of MCP-1 (monocyte 
      chemoattractant protein-1) as well as myocardial macrophage infiltration were 
      analysed. Treatment with atorvastatin significantly improved post-MI LV function 
      (fractional shortening, +120%; dP/dt(max), +147%; and LV end-diastolic pressure, 
      -27%). Furthermore atorvastatin treatment markedly decreased the levels of 
      TNF-alpha, IL-6 and MCP-1, reduced myocardial infiltration of macrophages and 
      significantly increased myocardial and serum levels of the anti-inflammatory 
      cytokine IL-10. Thus the balance between pro-inflammatory and anti-inflammatory 
      cytokines was shifted in the anti-inflammatory direction, as shown by a 
      significantly decreased TNF-alpha/IL-10 ratio. Atorvastatin ameliorated early LV 
      remodelling and improved LV function in rats with HF subsequent to MI. Our study 
      suggests that the modulation of the balance between pro- and anti-inflammatory 
      cytokines towards the anti-inflammatory cytokine IL-10 is one salutary mechanism 
      underlying how atorvastatin influences post-MI remodelling and thus improves LV 
      function.
FAU - Stumpf, Christian
AU  - Stumpf C
AD  - Department of Cardiology, University of Erlangen-Nuremberg, Ulmenweg 18, 91054 
      Erlangen, Germany. ch.stumpf@web.de
FAU - Petzi, Sebastian
AU  - Petzi S
FAU - Seybold, Katrin
AU  - Seybold K
FAU - Wasmeier, Gerald
AU  - Wasmeier G
FAU - Arnold, Martin
AU  - Arnold M
FAU - Raaz, Dorette
AU  - Raaz D
FAU - Yilmaz, Atilla
AU  - Yilmaz A
FAU - Daniel, Werner G
AU  - Daniel WG
FAU - Garlichs, Christoph D
AU  - Garlichs CD
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Clin Sci (Lond)
JT  - Clinical science (London, England : 1979)
JID - 7905731
RN  - 0 (Cytokines)
RN  - 0 (Heptanoic Acids)
RN  - 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Pyrroles)
RN  - 130068-27-8 (Interleukin-10)
RN  - A0JWA85V8F (Atorvastatin)
SB  - IM
CIN - Clin Sci (Lond). 2009 Jan;116(1):37-9. PMID: 18973470
MH  - Animals
MH  - Atorvastatin
MH  - Cytokines/blood
MH  - Disease Models, Animal
MH  - Drug Evaluation, Preclinical/methods
MH  - Hemodynamics/drug effects
MH  - Heptanoic Acids/*therapeutic use
MH  - Hydroxymethylglutaryl-CoA Reductase Inhibitors/*therapeutic use
MH  - Inflammation Mediators/blood
MH  - Interleukin-10/*blood
MH  - Macrophages/pathology
MH  - Male
MH  - Myocardial Infarction/blood/*drug therapy/pathology/physiopathology
MH  - Pyrroles/*therapeutic use
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Ventricular Dysfunction, Left/blood
MH  - Ventricular Function, Left/*drug effects
EDAT- 2008/05/08 09:00
MHDA- 2009/02/21 09:00
CRDT- 2008/05/08 09:00
PHST- 2008/05/08 09:00 [pubmed]
PHST- 2009/02/21 09:00 [medline]
PHST- 2008/05/08 09:00 [entrez]
AID - CS20080042 [pii]
AID - 10.1042/CS20080042 [doi]
PST - ppublish
SO  - Clin Sci (Lond). 2009 Jan;116(1):45-52. doi: 10.1042/CS20080042.